Zejing Pharmaceuticals (688266.SH): the clinical trial of the combination of injectable ZG005 and injectable ZG006 has been approved.

Zhijian Finance APP News, Zejing Pharmaceutical (688266.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The clinical trial of ZG005 for injection and ZG006 for injection used in combination for advanced small cell lung cancer or neuroendocrine cancer has been approved.